Company Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.
The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.
ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1993 |
| IPO Date | May 27, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 598 |
| CEO | Catherine Owen Adams |
Contact Details
Address: 12830 El Camino Real, Suite 400 San Diego, California 92130 United States | |
| Phone | 858 558 2871 |
| Website | acadia.com |
Stock Details
| Ticker Symbol | ACAD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070494 |
| CUSIP Number | 004225108 |
| ISIN Number | US0042251084 |
| Employer ID | 06-1376651 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Catherine E. Owen Adams | Chief Executive Officer and Director |
| Mark C. Schneyer | Executive Vice President and Chief Financial Officer |
| Brendan P. Teehan | Executive Vice President, Chief Operating Officer and Head of Commercial |
| Stephen R. Davis J.D. | Consultant |
| James K. Kihara | Vice President, Chief Accounting Officer and Corporate Controller |
| Dr. Elizabeth H.Z. Thompson Ph.D. | Executive Vice President and Head of Research and Development |
| Benir Ruano | Senior Vice President of Technical Development, Operations and Quality |
| Albert S. Kildani | Senior Vice President of Investor Relations and Corporate Communications |
| Jennifer J. Rhodes J.D. | Executive Vice President, Chief Legal Officer and Secretary |
| Holly Valdiviez | Senior Vice President and Head of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Sep 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |